Vaccines

1 August 2017

Dynavax Announces FDA Advisory Committee Vote in Favor of HEPLISAV-B

29 July 2017

VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine

27 July 2017

Chikungunya-fever: Themis Bioscience starts phase II clinical study in endemic area

27 July 2017

CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

27 July 2017

Emergent BioSolutions Secures Exclusive Worldwide Rights to Valneva’s Zika Vaccine Technology

25 July 2017

Novavax Announces Positive Topline Data from Phase 2 Older Adult Trial and Provides Path Forward for RSV F Vaccine Programs

24 July 2017

Genocea Reports Positive Top-Line 12-Month Phase 2b Data for GEN-003 in Genital Herpes

24 July 2017

Johnson & Johnson Announces Encouraging First-in-Human Clinical Data for Investigational HIV Preventive Vaccine

24 July 2017

VALNEVA Receives FDA Fast Track Designation for its Lyme Disease Vaccine Candidate VLA15

20 July 2017

BriaCell Provides Clinical Update on its Ongoing Phase I/IIa Clinical Study of BriaVaxTM in Advanced Breast Cancer

19 July 2017

Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer

18 July 2017

AXON’s Tau Vaccine Has Completed Phase II Enrolment in Alzheimer’s

14 July 2017

Publication in Cell Demonstrates Moderna’s Zika mRNA Vaccine Prevents In Utero Transmission of Zika Virus in Mice, Protects Against Zika-Related Congenital Damage

12 July 2017

Meissa Vaccines awarded $1.6m Fast Track SBIR Grant to advance IND preparations for RSV vaccine candidate

6 July 2017

Nature Publication Reports Favorable Clinical Trial Results of BioNTech’s Individualized Cancer Vaccine IVAC® MUTANOME

6 July 2017

Initial Results from Dana-Farber Cancer Institute Personalized Neoantigen Vaccine Published in Nature

5 July 2017

Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy

30 June 2017

ALK: Five-year GRAZAX® Asthma Prevention (GAP) Trial Reveals Benefits of Early Treatment Intervention in Children

27 June 2017

Araclon Biotech initiates phase II clinical trials of its Alzheimer’s vaccine

27 June 2017

GSK receives CHMP positive opinion for Synflorix pneumococcal vaccine four-dose vial

27 June 2017

OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi® in Advanced Lung Cancer

21 June 2017

ImmunoCellular Therapeutics Provides Update on Strategic Review and Decision to Suspend Further Patient Randomization for ICT-107 Phase 3 Trial

21 June 2017

GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC’s Advisory Meeting

21 June 2017

NanoBio And Porton Biopharma Receive Approval To Advance Next Generation Anthrax Vaccine

21 June 2017

Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA® (pembrolizumab), for the Treatment of HPV-Induced Cervical Cancer

21 June 2017

Pfizer Begins Phase 1 Clinical Trial to Evaluate Investigational Group B Streptococcus Vaccine

15 June 2017

Inovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution

13 June 2017

Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy

13 June 2017

Autoantigen GAD-Vaccine is Safe for Children at High Risk for Developing Type 1 Diabetes

11 June 2017

Inovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

CD73 Inhibitor Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

GPC3-Targeted Immunotherapy Pipeline Review

5T4-Targeted Immunotherapy Candidates Pipeline Review

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

c-Met-Targeted Antibody Therapy Pipeline Review